Search

Displaying results 1961 - 1970 of 10000 in total
  1. Drug

    Trazodone

    go.drugbank.com/drugs/DB00656
    ApprovedInvestigational

    receptor inhibitor (SNRIs) in the treatment of depression. … [T646] It was initially granted FDA approval in 1981.[L3484]

  2. Drug

    Vemurafenib

    go.drugbank.com/drugs/DB08881
    ApprovedInvestigational

    After approval, Roche in collaboration with Genentech launched a broad development program. [L1012] … [A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche.

  3. Drug

    Mavorixafor

    go.drugbank.com/drugs/DB05501
    ApprovedInvestigational

    mavorixafor is being investigated in these conditions. … [L50647] WHIM syndrome is caused by mutations in the _CXCR4_ gene, which leads to overactivation of CXCR4 signalling pathways.[A263652] Mavorixafor prevents the activation of CXCR4.

    Synonyms: 1,4-BUTANEDIAMINE, N-(1H-BENZIMIDAZOL-2-YLMETHYL)-N-((8S)-5,6,7,8-TETRAHYDRO-8-QUINOLINYL)-
  4. Drug

    Methacholine

    go.drugbank.com/drugs/DB06709
    Approved

    Asthma is a complex condition associated with phenomena such as airway hyperresponsiveness (AHR), in which the smooth muscle in the airways (ASM) excessively contracts in response to stimuli, reducing … [A229648, L31763] Methacholine was granted FDA approval on October 31, 1986, and is marketed under the trademark PROVOCHOLINE® by Methapharm Inc.[L31763]

  5. Drug

    Bedaquiline

    go.drugbank.com/drugs/DB08903
    ApprovedInvestigational

    [A261856] Currently, bedaquiline is the last-line anti-TB drug and must only be used in an appropriate combination regimen.[L48506,A261866] … [A261856,A261861] It is the first drug that was approved in the last 40 years by the FDA for TB unresponsive to current treatments on the market.

  6. Drug

    Fruquintinib

    go.drugbank.com/drugs/DB11679
    ApprovedInvestigational

    This approval is based on favorable results obtained from the FRESCO and FRESCO-2 trials, where an increase in overall survival rate was observed in both trials.[L48791] … -, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.

  7. Drug

    Levothyroxine

    go.drugbank.com/drugs/DB00451
    ApprovedInvestigational

    [F4633] T<sub>4</sub> and T<sub>3</sub> act on nearly every cell of the body, but have a particularly strong effect on the cardiac system. … the thyroid gland is no longer able to produce sufficient quantities of the thyroid hormones T<sub>4</sub> (tetraiodothyronine or thyroxine) and T<sub>3</sub> (triiodothyronine or [DB00279]), resulting in

  8. Drug

    Efinaconazole

    go.drugbank.com/drugs/DB09040
    ApprovedInvestigational

    It was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia. … Efinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis.

  9. Drug

    Butalbital

    go.drugbank.com/drugs/DB00241
    ApprovedIllicit

    Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. … [L10370] Butalbital‐containing analgesics can also produce a drug‐induced headache in addition to tolerance and dependence.

    Synonyms: 5-allyl-5-(2'-methyl-n-propyl) barbituric acid
  10. Drug

    Emedastine

    go.drugbank.com/drugs/DB01084
    Approved

    Emedastine is an antihistamine used in eye drops to treat allergic conjunctivitis.